ARA-290: Dosage, Protocol, and Research Guide
Non-erythropoietic EPO derivative with tissue-protective properties
Mechanism
Activates innate repair receptor, reduces inflammation, promotes nerve regeneration, improves metabolic function
Protocol at a glance
| Starting dose | 2mg |
|---|---|
| Maintenance dose | 2-4mg |
| Maximum dose | 4mg |
| Frequency | 3x weekly |
| Typical duration | 4-12 weeks |
| Route | Subcutaneous |
| Injection site | Abdomen |
| Timing | Any time |
Side effects
- Minimal - mild injection site reactions
Contraindications
- Active cancer (theoretical concern)
Protocol notes
- Excellent for neuropathy
- Reduces pain and inflammation
- Promotes nerve healing
- No effect on red blood cells
- Well-tolerated in clinical trials
Frequently asked questions
What is ARA-290 and how does it work?
ARA-290 is a non-erythropoietic EPO derivative that activates the innate repair receptor to provide tissue-protective properties. Unlike traditional EPO derivatives, ARA-290 focuses on reducing inflammation, promoting nerve regeneration, and improving metabolic function without affecting red blood cell production. This mechanism makes it distinct in healing-focused peptide protocols.
What is the standard dosing protocol for ARA-290?
Standard protocols begin with a 2mg starting dose, administered subcutaneously into the abdomen. Maintenance dosing ranges from 2-4mg, with a maximum dose of 4mg. The typical frequency is three times per week, and protocols generally run for 4-12 weeks. ARA-290 can be injected at any time of day, providing flexibility in administration timing.
What side effects does ARA-290 have?
Side effects with ARA-290 are minimal. The most commonly reported adverse effect is mild injection site reactions at the abdomen injection site. The peptide is well-tolerated in clinical trials and does not affect red blood cell production, avoiding the hematological side effects associated with traditional EPO derivatives. The only theoretical contraindication is active cancer.
Is ARA-290 legal?
Legality of ARA-290 varies by jurisdiction. In many countries, it is available for research purposes only and is not FDA-approved for human use. Regulatory status differs globally, so it's essential to verify local laws before obtaining or using ARA-290. Always consult a licensed physician before considering use.
What results should I expect from an ARA-290 protocol?
ARA-290 is particularly excellent for neuropathy management. Users following research protocols may experience reduced pain and inflammation, particularly in neuropathic conditions. The peptide actively promotes nerve healing and regeneration, which can lead to gradual improvements in nerve function over the course of a 4-12 week protocol. Because ARA-290 does not stimulate red blood cells, you won't experience the systemic effects associated with erythropoietic agents.
Can I cycle or stack ARA-290 with other compounds?
Standard protocols run for 4-12 weeks at three times weekly dosing. Research on optimal cycling strategies—including break periods or multi-cycle approaches—remains limited. Stacking protocols should only be undertaken under medical supervision, as research on ARA-290 interactions with other peptides remains limited. The appropriate approach for your individual situation should be determined by a licensed physician.
What lab markers should I monitor while using ARA-290?
Because ARA-290 does not affect red blood cell production, standard CBC markers used to monitor traditional EPO derivatives are not applicable. Research on specific lab markers for monitoring ARA-290 remains limited. Medical supervision is essential to determine which baseline labs and follow-up testing are appropriate for your individual protocol and health status.
More Healing & Recovery peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.